City of Hope Medical Center: Glioblastoma trials

The registry lists 19 Glioblastoma studies with City of Hope Medical Center as lead sponsor. 6 are open to participants now and 3 have results posted.

Phase 1 17No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With GlioblastomaNot yet recruitingNCT07791264Phase 1
• Tear Fluid for the Detection of Tumor-associated Extracellular Vesicles in Glioblastoma PatientsRecruitingNCT07775534Not applicable
• Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against CancerRecruitingNCT07664579
• Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade GliomasRecruitingNCT07544992Phase 1
• Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant AstrocytomaRecruitingNCT06815029Phase 1
• Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade GliomasRecruitingNCT05139056Phase 1
• Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant GliomaActive, not recruitingNCT02208362Phase 1Results posted
• Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade GliomasActive, not recruitingNCT02192359Phase 1Results posted
• Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade GliomasCompletedNCT02015819Phase 1Results posted
• Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with GlioblastomaWithdrawnNCT05773664Phase 1
• Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or MedulloblastomaActive, not recruitingNCT04661384Phase 1
• Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive GlioblastomaActive, not recruitingNCT04214392Phase 1
• IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBMActive, not recruitingNCT04003649Phase 1
• Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV GliomaActive, not recruitingNCT03389230Phase 1
• Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade GliomasWithdrawnNCT02055196Phase 1
• Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain MetastasesCompletedNCT01234740Phase 1
• A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade GliomasCompletedNCT01172964Phase 1
• Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2CompletedNCT01082926Phase 1
• Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant GliomaCompletedNCT00730613Phase 1